Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Viracept opvejer risiciene ved antiretroviral kombinationsbehandling af voksne, unge og børn i alderen tre år eller derover, der er smittet med human immundefekt virus (HIV- 1).
The Committee for Medicinal Products for Human Use (CHMP) decided that Viracept’ s benefits are greater than its risks in antiretroviral combination treatment of HIV-1 infected adults, adolescents and children of three years of age and older.